Floatz logo

Dexmedetomidine

Liver Cancer

Uppsala University HospitalSmall moleculePhase 4 / ApprovedDormant
BBB
73/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
59/ 100
Competitive Position
95/ 100

Competitive context

111 Active assets in the Liver Cancer cohort.

Asset / SponsorPhaseRating
DOXORUBICIN
Shanghai Zhongshan Hospital
Phase 4BB
OXALIPLATIN
Sun Yat-sen University
Phase 3BB
Idarubicin
Second Affiliated Hospital of Guangzhou Medical University
Phase 3BB
Hepatitis B Virus Vaccine
Eunice Dube
Phase 4BB
Gardasil 9 Vaccine
Eunice Dube
Phase 4BB

View all 50 →

Same molecule, other indications

Dexmedetomidine is also rated in:

schizophreniform disorderDormant
A
Indicative ·
80 / 100
View asset →
schizoaffective disorderDormant
BBB
Indicative ·
77 / 100
View asset →
neuralgiaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →